Featuring the pros and cons of ‘patient-orientated research’, a new addition to the Medical Publishing and Insights Practices (MPIP) open access toolkit and an update on Plan S.
Featuring concerns over financing ‘pay to publish’ models, a fresh demand for clinical trial transparency sanctions, and how one highly cited article may influence a journal’s impact factor and a researcher’s career progression.
Featuring the growing need for communication during each stage of the research process, the role of patient experts in a healthcare setting, the association of medical writing support with the quality of clinical trial reporting, and the replacement of supplementary material with online repositories.
Featuring a patient’s perspective on the Health Research Authority’s transparency consultation, the launch of the Journal of Trial and Error and the call for ResearchGate to educate users on responsible content sharing.
Featuring the use of ‘spin’ in clinical trial abstracts, the first publication in UCL Open: Environment, a new clinical trial educational resource and insights from the OASPA webinar on learned societies and open access.
Featuring the release of the AMWA-EMWA-ISMPP position statement on predatory publishing, the hidden disclosures of medical journal editors, the citation advantage of preprints and the launch of the Open Pharma Calendar of Open Access Events
Featuring the lack of transparency across clinical trials in French hospitals, the introduction of Registered Reports, the data detective who protects patients and one patient advocate’s experience with the medical publishing process
Featuring a summary of the Open Pharma team’s trip to Evidence-Based Medicine Live 2019, the potential use of Literature Programming to improve research transparency, a new data depot project in India and the lack of institutional incentives for researchers to publish open access
Featuring the latest results from the Good Pharma Scorecard, the newest signatories to DORA, incentives for sharing data and potential barriers to mandating open access.
Featuring the predatory market for fake science, the paywall surrounding Cabell’s blacklist and the success of medRxiv